A Study to Evaluate the Safety and Pharmacokinetics of BX-001N in Healthy Participants
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, single and multiple ascending dose,
Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of BX-001N after
intravenous administration in approximately 64 healthy participants